| abstract |
The present disclosure includes the identification of molecular markers including ASPM, ATP9A, ACOX3, CDC45L, SLC40A1, AGR2, and those listed in Table 2 that are associated with clinical prognosis of differentiation and pancreatic cancer. More specifically, the present disclosure includes the identification of a set of genetic markers that can be used to distinguish a highly differentiated pancreatic cancer from a less differentiated pancreatic cancer. These markers can be used to predict the clinical prognosis of pancreatic cancer, including host disease progression, recurrence or death. In addition, the present disclosure also relates to glandular tumors such as pancreatic cancer, breast cancer and prostate cancer by inhibiting ASPM expression or the ability of ASPM to activate or retain the Wnt signaling activity and / or cancer stem cell population of the above adenocarcinoma. Methods and kits for treating adenocarcinoma for assaying cancer are provided. [Selection] Figure 19D |